Published By : 26 Jun 2018 | Published By : QYRESEARCH
How successful was the gene therapy can now be measured via new method of molecular imaging, which can monitor all portions of brain, allowing doctors to effectively tackle brain’s condition such as Alzheimer’s disease, Parkinson’s disease, and numerous sclerosis. 2018 SNMMI Annual Meeting, which took place in Philadelphia, presented this research.
The usage of gene therapy for diseases of the central nervous system is expanding but the progress is dwarfed by the lack of suitable imaging techniques. Albeit, reporter gene system have been a vital tool in the imaging of molecular for years. A newly discovered positron emission tomography (PET) reporter gene marks it conceivable to noninvasively screen the level of gene appearance in brain, providing the health team an upper hand.
Thomas Haywood, who holds a Ph.D. from radiology department at the Stanford University, California, said that  F-DASA- 23 is an innovative radioactive tracer, which is proficient at intersecting the brain-blood barricade aiming the pyruvate kinase M2 protein in CNS. The radioactive tracer recently underwent first human test at Stanford for the primary finding of remedial reaction in glioblastoma.
After confirming the effectiveness of PET reporter gene by pyruvate kinase M2 (PKM2), mice were infected and imaged with  F-DASA-23 radioactive tracer, which showed that there was a decent connection between PKM2 and the radioactive tracer. These result further encouraged that PKM2 can be further advanced into a molecular imagining of PET reporter gene system meant for the gene therapy imaging.